New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
10:07 EDTSCHW, VAR, ALKS, AMTD, AGN, CHMT, ETFCOn The Fly: Analysts Initiation Summary
Today's noteworthy initiations include: Allergan (AGN) initiated with a Buy at SunTrust...Varian Medical (VAR) initiated with a Buy at Benchmark Co. and with a Buy at SunTrust...E-Trade (ETFC) initiated with a Neutral at Compass Point...TD Ameritrade (AMTD) initiated with a Neutral at Compass Point...Charles Schwab (SCHW) initiated with a Neutral at Compass Point...Chemtura (CHMT) initiated with a Buy at KeyBanc...Alkermes (ALKS) initiated with a Buy at Mizuho.
News For AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
07:17 EDTAGNAllergan announces FDA approval of updated label for TEFLARO
Subscribe for More Information
07:09 EDTAGNAllergan announces topline results from RECAPTURE 1 and 2
Allergan announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ as a treatment for adult hospitalized patients with complicated urinary tract infections, including pyelonephritis. AVYCAZ consists of a cephalosporin, ceftazidime, an established treatment for serious bacterial infections, and the first and only non-beta lactam beta-lactamase inhibitor, avibactam. The addition of avibactam protects ceftazidime from being broken down by certain beta-lactamases that are produced by these resistant bacteria. The global RECAPTURE 1 and 2 Phase III studies evaluated the safety and efficacy of AVYCAZ administered intravenously as a two-hour infusion, compared to doripenem, administered intravenously as a 30-minute infusion, in hospitalized adult patients with cUTI, including pyelonephritis. Data from the studies were analysed as a single-pooled dataset with the agreement of the US FDA and the EMA. AVYCAZ was also effective in treating cUTI patients infected with ceftazidime-resistant bacteria. Allergan plans to submit this data as a supplemental New Drug Application (sNDA) to the Food and Drug Administration by the end of 2015.
September 1, 2015
10:04 EDTALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:25 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
07:11 EDTALKSMorgan Stanley ups Alkermes two notches with $85 price target
Subscribe for More Information
06:46 EDTALKSAlkermes upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
August 31, 2015
08:04 EDTAGNAllergan completes Nuarex acquisition
Subscribe for More Information
07:39 EDTAGNCiti calls Allergan a 'stock to own,' keeps $360 target
Citi analyst Liav Abraham calls Allergan a "stock to own" given its "attractive" organic growth profile, pipeline potential and ability to do more acquisitions. He reiterates a Buy rating on the stock with a $360 price target.
August 28, 2015
09:50 EDTAGNAllergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
09:36 EDTSCHWCharles Schwab says systems issues 'should now be resolved'
Subscribe for More Information
09:24 EDTSCHWCharles Schwab experiencing systems issues
Subscribe for More Information
August 25, 2015
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
August 24, 2015
11:03 EDTAMTDTD Ameritrade says in tweet, 'observing street wide latency issues'
Subscribe for More Information
09:41 EDTSCHWCharles Schwab fined $2M by FNRA for net capital deficiencies
Subscribe for More Information
08:37 EDTAGNAllergan recalls certain lots of REFRESH, FML, Blephamide treatments
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
08:11 EDTALKSAlkermes delay for Aristada due to administrative issues, says Jefferies
Jefferies said it appears that the FDA's delay in approving Alkermes' Aristada is due to the agency's need for some additional review time. The firm said the fact that the FDA did not choose to issue a CRL letter gives it confidence that Alkermes should receive full approval in a "few weeks" and it maintains its Buy rating and $76 price target on the stock.
August 21, 2015
16:01 EDTALKSAlkermes provides update on FDA review of ARISTADA
Alkermes announced that the U.S. FDA has advised Alkermes that it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia by the Prescription Drug User Fee Act action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time. "We are confident in the ARISTADA program and our NDA submission, and we will work closely with the FDA as they complete their review," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "We look forward to bringing ARISTADA to market as a potential new treatment option to help address the significant unmet medical needs of patients living with schizophrenia."
10:02 EDTVARHigh option volume stocks
High option volume stocks: XEO VAR AMCC XPO ROST INTU TFM BTE DXD
08:40 EDTAMTDCanadian Security Traders Association to hold a conference
Subscribe for More Information
August 20, 2015
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use